Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: This study was to assess the lot-to-lot consistency, immunogenicity and safety of three manufacturing lots of a quadrivalent inactivated influenza vaccine (IIV4).
Methods: A randomized, double-blind, phase IV clinical trial was conducted in healthy children, adolescents and adults aged 9-59 years in Guizhou Province, China. Eligible participants were enrolled and randomized into three groups in a ratio of 1:1:1 to receive a single dose of one of three manufacturing lots of IIV4. Serum samples were collected before and 28 days after vaccination for hemagglutination inhibition (HI) antibody testing. Safety data were collected for up to 28 days after vaccination. The primary objective was to evaluate the lot-to-lot consistency of immune response as assessed by the geometric mean titer (GMT) of HI antibody at 28 days after vaccination.
Results: Between November 27, 2022 and December 18, 2022, 1260 eligible participants were enrolled, with similar participant demographics among groups. Immune responses after vaccination were comparable across groups, with the 95% confidence intervals (CIs) of GMT ratios for all 4 strains falling into the equivalence criterion of (0.67, 1.5). The seroconversion rates (SCRs) and seroprotection rates (SPRs) met the US Center or Biologics Evaluation and Research (CBER) criteria for all strains for each lot (lower limit of 95% CI of SCR ≥ 40% and SPR ≥ 70%). The incidences of solicited and unsolicited adverse reactions were similar among three groups, most of which (91.9%) were mild or moderate in severity. A total of 11 serious adverse events were reported during the study, and all were considered unrelated to vaccination.
Conclusion: The three manufacturing lots of IIV4 demonstrated consistent immunogenicity. IIV4 can elicit satisfactory immune responses for all four strains and no safety concerns were identified.
Clinical Trial Registration: Identifier No. NCT05512494.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2024.126182 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High Performance Monometallic Platinum Fuel Cell Catalyst Derived from Self-Hole-Confined Nanoparticles and Nitrogen-Anchored Single-Atoms.
Small Methods
September 2025
Research Center for Analysis and Measurement, Faculty of Materials Science and Engineering, Kunming University of Science and Technology, Kunming, 650093, P. R. China.
Platinum and non-precious metal (PtM) alloy multimetallic catalysts have been developed to address the kinetically sluggish oxygen reduction reaction (ORR) occurring at the cathodes of proton exchange membrane fuel cells (PEMFCs). However, these catalysts inevitably suffer from poor lot-to-lot consistency of chemical compositions and structures during production, and the transition metal leaching in practical applications. Thus, the development of high-performance monometallic Pt catalysts using innovative nanoarchitectures has become important to address the technical challenges that hinder the widespread deployment of the PEMFCs.
View Article and Find Full Text PDFMicroflow LC-MS/MS reveals platform-specific post-translational modification signatures in recombinant adeno-associated virus capsids linked to enhanced potency and stability: A quality control framework for gene therapy.
J Pharm Biomed Anal
December 2025
NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control, No. 2, Tiantan Xili, Beijing 100050, China. Electronic address:
Recombinant adeno-associated viruses (rAAVs) are pivotal gene therapy vectors due to their safety and stable transduction, yet comprehensive characterization of capsid post-translational modifications (PTMs)-critical for potency, immunogenicity, and manufacturing consistency-remains limited across production platforms. This study employs microflow LC-MS/MS coupled with electron-activated dissociation (EAD) to analyze PTMs in clinically relevant rAAV5 and rAAV9 serotypes produced via mammalian (HEK293) and insect (Sf9) cells, with parallel cellular-level evaluation of vector potency and infectivity, conducted under matched purity and capsid thermal stability conditions to isolate PTM-specific effects. Intact mass analysis revealed conserved N-terminal acetylation in VP1/VP3 across both platforms, while PTM profiling identified six distinct modification types, including deamidation, oxidation, and phosphorylation, with Sf9-derived vectors exhibiting 14 % more PTMs than HEK293-produced counterparts.
View Article and Find Full Text PDFIn Vitro Assessment of Drug-Induced Liver Injury Using Three-Dimensional Cultured HepaSH Cells Derived From Chimeric Mouse Model With Humanized Liver.
J Appl Toxicol
July 2025
Division of Pharmacology, National Institute of Health Sciences, Kawasaki, Japan.
Drug-induced liver injury (DILI) is a serious adverse event and a common cause of postmarketing drug withdrawal. Despite nonclinical assessments of DILI risk, which are predominantly conducted in experimental animals, DILI remains a frequent adverse event, highlighting the need to improve nonclinical assessments. Extensive studies have demonstrated that primary human hepatocytes (PHHs) and their three-dimensional (3D) cultures, such as spheroids, exhibit high predictability of drug-induced hepatotoxicity in vitro.
View Article and Find Full Text PDFStandardising EQA submissions with automated defactoring of post-analytical correction factors.
Clin Chim Acta
September 2025
Royal College of Pathologists of Australasia Quality Assurance Programs, Herbert Street, St Leonards, NSW, Australia.
Post Analytical Correction Factors are routinely applied by clinical laboratories to align results from different instruments, methods, or because of the need to maintain consistent results in the face of lot-to-lot reagent variation, or if a new method introduces a bias compared to the technique from which the reference interval was derived. In any of these situations, some procedures must be followed to ensure that the factor used to align results from different methods, procedures, or reagents is valid and robust. In addition to the problems a laboratory faces in deriving and managing these factors, poorly described procedures exist for submitting results for External Quality Assurance (EQA) challenges.
View Article and Find Full Text PDFEnvironmental factors capable of broadly interfering with nutritional lifespan extension paradigms.
iScience
July 2025
Department of Medicine, Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Despite being principally prescribed to treat type 2 diabetes, biguanides, especially metformin and phenformin, have been shown to extend lifespan and healthspan in preclinical models. Although there have been conflicting results in studies involving rodents and humans, consistent evidence indicates metformin and phenformin's ability to significantly extend lifespan in . We find that variation in agar from lot-to-lot or from different manufacturers influences metformin's ability to extend lifespan in diverse species.
View Article and Find Full Text PDF